RU2002133868A - CANNABINOID MEDICINES - Google Patents

CANNABINOID MEDICINES

Info

Publication number
RU2002133868A
RU2002133868A RU2002133868/15A RU2002133868A RU2002133868A RU 2002133868 A RU2002133868 A RU 2002133868A RU 2002133868/15 A RU2002133868/15 A RU 2002133868/15A RU 2002133868 A RU2002133868 A RU 2002133868A RU 2002133868 A RU2002133868 A RU 2002133868A
Authority
RU
Russia
Prior art keywords
compound
mammal
alkyl
cell proliferation
administered
Prior art date
Application number
RU2002133868/15A
Other languages
Russian (ru)
Other versions
RU2273476C2 (en
Inventor
Самнер БЕРСТАЙН
Лоуренс РЕХТ
Роберт Б. ЦУРИЕР
Original Assignee
Атлэнтик Текнолоджи Венчурс, Инк.
Лоуренс РЕХТ
ЦУРИЕР Роберт Б
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Атлэнтик Текнолоджи Венчурс, Инк., Лоуренс РЕХТ, ЦУРИЕР Роберт Б filed Critical Атлэнтик Текнолоджи Венчурс, Инк.
Publication of RU2002133868A publication Critical patent/RU2002133868A/en
Application granted granted Critical
Publication of RU2273476C2 publication Critical patent/RU2273476C2/en

Links

Claims (17)

1. Способ снижения клеточной пролиферации у млекопитающего, включающий определение млекопитающего, для которого желательно снижение клеточной пролиферации, и введение этому млекопитающему соединения формулы1. A method of reducing cell proliferation in a mammal, comprising determining a mammal for which reduction of cell proliferation is desired, and administering to the mammal a compound of the formula
Figure 00000001
Figure 00000001
 где R1 представляет собой атом водорода, -СОСН3 или СОСН2СН3;where R 1 represents a hydrogen atom, —COCH 3 or COCH 2 CH 3 ; R2 представляет собой разветвленный С5-С12алкил, в количестве, эффективном для снижения клеточной пролиферации у млекопитающего.R 2 is a branched C 5 -C 12 alkyl, in an amount effective to reduce cell proliferation in a mammal. 2. Способ по п.1, где R1 представляет собой водород.2. The method according to claim 1, where R 1 represents hydrogen. 3. Способ по п.2, где R2 представляет собой С9алкил.3. The method according to claim 2, where R 2 represents C 9 alkyl. 4. Способ по п.3, где С9алкил является разветвленным алкилом.4. The method according to claim 3, where C 9 alkyl is branched alkyl. 5. Способ по п.4, где разветвленный алкил является 1,1-диметилгептилом.5. The method according to claim 4, where the branched alkyl is 1,1-dimethylheptyl. 6. Способ по п.1, где R2 представляет собой С9алкил.6. The method according to claim 1, where R 2 represents C 9 alkyl. 7. Способ по п.6, где С9алкил является разветвленным алкилом.7. The method according to claim 6, where C 9 alkyl is branched alkyl. 8. Способ по п.1, где разветвленный алкил является 1,1-диметилгептилом.8. The method according to claim 1, where the branched alkyl is 1,1-dimethylheptyl. 9. Способ по п.1, в котором млекопитающее является человеком.9. The method according to claim 1, in which the mammal is a human. 10. Способ по п.1, где соединение вводится орально.10. The method according to claim 1, where the compound is administered orally. 11. Способ по п.1, где соединение вводится системно (систематически).11. The method according to claim 1, where the compound is administered systemically (systematically). 12. Способ по п.1, где соединение вводится через имплантат.12. The method according to claim 1, where the compound is introduced through the implant. 13. Способ по п.12, где имплантат обеспечивает медленное выделение соединения.13. The method of claim 12, wherein the implant provides a slow release of the compound. 14. Способ по п.1, где соединение вводится внутривенно.14. The method according to claim 1, where the compound is administered intravenously. 15. Способ по п.1, где клеточная пролиферация связана с раком.15. The method according to claim 1, where cell proliferation is associated with cancer. 16. Способ по п.1, где количество вводимого соединения составляет от около 0,1 до 20 мг/кг массы тела млекопитающего.16. The method according to claim 1, where the amount of the administered compound is from about 0.1 to 20 mg / kg body weight of a mammal. 17. Способ по п.16, где количество вводимого соединения составляет от около 0,2 до 2 мг/кг массы тела млекопитающего.17. The method according to clause 16, where the amount of the administered compound is from about 0.2 to 2 mg / kg of body weight of a mammal.
RU2002133868/15A 2000-05-17 2001-05-17 Cannabinoid drugs RU2273476C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20493500P 2000-05-17 2000-05-17
US60/204,935 2000-05-17

Publications (2)

Publication Number Publication Date
RU2002133868A true RU2002133868A (en) 2004-06-27
RU2273476C2 RU2273476C2 (en) 2006-04-10

Family

ID=22760084

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2002133868/15A RU2273476C2 (en) 2000-05-17 2001-05-17 Cannabinoid drugs
RU2002133869/14A RU2272620C2 (en) 2000-05-17 2001-05-17 Method for decreasing cell proliferation based upon (3r,4r)- △8-tetrahydrocannabinol-11-onic acids (hemp-obtained acids)

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2002133869/14A RU2272620C2 (en) 2000-05-17 2001-05-17 Method for decreasing cell proliferation based upon (3r,4r)- △8-tetrahydrocannabinol-11-onic acids (hemp-obtained acids)

Country Status (13)

Country Link
US (2) US6448288B1 (en)
EP (2) EP1307188B1 (en)
JP (2) JP2003533478A (en)
CN (2) CN1273123C (en)
AT (1) ATE406156T1 (en)
AU (5) AU2001263217A1 (en)
CA (2) CA2409005A1 (en)
DE (1) DE60135557D1 (en)
HU (2) HUP0700038A2 (en)
IL (3) IL152891A0 (en)
NZ (2) NZ523029A (en)
RU (2) RU2273476C2 (en)
WO (3) WO2001087296A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1509250B1 (en) 2002-06-06 2008-05-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
AU2003303376A1 (en) * 2002-12-19 2004-07-22 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
DE602004031221D1 (en) * 2003-05-20 2011-03-10 Univ Tennessee Res Foundation CANNABINOID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
US20060128794A1 (en) 2004-12-13 2006-06-15 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using (6aR,10aR)-delta8-tetrahydrocannabinol-11-OIC acids
US20060128738A1 (en) * 2004-12-13 2006-06-15 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
CA2623723A1 (en) 2005-09-29 2007-04-12 Amr Technology, Inc. Process for production of delta-9-tetrahydrocannabinol
WO2007047010A2 (en) * 2005-10-20 2007-04-26 Indevus Pharmaceuticals, Inc. Anti-emetic uses of cannabinoid analogs
US20070099988A1 (en) * 2005-10-31 2007-05-03 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (en) 2006-12-30 2008-07-31 Abbott Gmbh & Amp OXINDOL DERIVATIVES REPLACED, MEDICINES THAT UNDERSTAND AND USE THEMSELVES
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
WO2008144475A1 (en) 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
JP5645217B2 (en) 2007-12-07 2014-12-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 5,6-disubstituted oxindole derivatives and their use to treat vasopressin-dependent diseases
JP5701607B2 (en) 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Amidomethyl-substituted oxindole derivatives and their use in the treatment of vasopressin-dependent diseases
BRPI0820668A2 (en) 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg 5-HALOGEN SUBSTITUTED OXINDOL DERIVATIVES AND THEIR USE TO TREAT VASOPRESSIN DEPENDENT DISEASES
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
AU2018311966A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Benzo[b]thiophene sting agonists for cancer treatment
WO2019027857A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND BENZO[b]THIOPHENE STING AGONISTS FOR CANCER TREATMENT
CN111233814A (en) * 2020-03-02 2020-06-05 福建省中科生物股份有限公司 Terpene phenolic compound ZKYY-057 and preparation method and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327028A (en) * 1978-08-17 1982-04-27 Calcol, Inc. Composition of matter
ZA885929B (en) * 1987-08-25 1989-04-26 Oxi Gene Inc Agents for use in tumor or cancer cell killing therapy
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US4880030A (en) * 1988-07-25 1989-11-14 Terry Paul E Safety flow control fluid shutoff device
US5635530A (en) * 1991-09-12 1997-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5538993A (en) * 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6162829A (en) * 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
ES1045342Y (en) * 2000-02-11 2001-02-16 Alvarez Manuel Couto ROTATING EXHIBITOR FOR POSTCARDS, PHOTOS AND SIMILAR.

Similar Documents

Publication Publication Date Title
RU2002133868A (en) CANNABINOID MEDICINES
RU2002133869A (en) WAYS TO REDUCE CELL PROLIFERATION BASED ON (3R, 4R) C1-8 - TETRAHYDROCANABINOL-11-ONE ACIDS (HEMP ACID)
CA2430692A1 (en) Geldanamycin derivative and use of same to treat cancer
KR920700200A (en) 19-nor-vitamin D compound
RU2694361C3 (en) LACENTIVE COMPOSITION
CA2333965A1 (en) Method of enhancing lysosomal .alpha.-galactosidase a
KR950031068A (en) Combined Treatment of Osteoporosis
KR900011772A (en) 3- (1,2,5,6-tetrahydropyridyl) pyrrolopyridine
CA2153979A1 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
JP2003533479A5 (en)
RU2003109622A (en) LIABILITY COMPOSITION
KR950032258A (en) Sulfated Alpha (α) -Glycolipid Derivatives as Cell Adhesion Inhibitors
RU2012110380A (en) NEW 5-Fluorouracil Derivative
EP1623985A3 (en) Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventative agents
DE69627170D1 (en) NON-AFFYANT REMEDIES FOR THE COLON
RU94037235A (en) Inhibitor of uterus fibrosis
DE60014916D1 (en) The use of a benzimidazole for the manufacture of a medicament for cancer prevention
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
RU2002123641A (en) S-4 carbonate-containing taxanes
CA2448278A1 (en) Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception
HUP0301773A2 (en) Apomorphine derivatives and methods for their use
RU2003133924A (en) DEUTERED 3-PIPERIDINOETHYLPHENYLKETONES, AND ALSO MEDICINES CONTAINING THESE COMPOUNDS
ATE156119T1 (en) 2-FORMYLPYRIDINE THIOSEMICARBAZONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS
CA2438509A1 (en) Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria
CA2373634A1 (en) Isophosphoramide mustard analogs and use thereof